专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110059899A1 Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein 审中-公开
标题翻译： Kruppel样因子6（KLF6），肿瘤抑制蛋白，以及基于该蛋白质的诊断，治疗和筛选
公开(公告)号：US20110059899A1
公开(公告)日：2011-03-10
申请号：US12769595
申请日：2010-04-28
申请人： Scott Friedman , Dan Li , Goutham Narla , John Martignetti , Karen Heath
发明人： Scott Friedman , Dan Li , Goutham Narla , John Martignetti , Karen Heath
IPC分类号： A61K38/17 , A61K31/7088 , A61P35/00 , C12Q1/68 , G01N33/53 , C12Q1/48 , C12Q1/28 , C12N5/02 , C12N15/63
CPC分类号： A61K48/005 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/154 , C12Q2600/172 , G01N33/57407 , G01N2333/4703
摘要： The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.
摘要翻译：本发明涉及鉴定蛋白质KLF6（KLF6）的肿瘤抑制活性以及相关的诊断和治疗组合物和方法。这种肿瘤抑制活性的发现也提供筛选目标，特别是筛选克隆基因失活或改变的化合物。

2. 发明申请

US20050181374A1 Kruppel-like factor 6 ( KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein 审中-公开
标题翻译： Kruppel样因子6（KLF6），肿瘤抑制蛋白，以及基于该蛋白质的诊断，治疗和筛选
公开(公告)号：US20050181374A1
公开(公告)日：2005-08-18
申请号：US10752079
申请日：2004-01-05
申请人： Scott Friedman , Dan Li , Goutham Narla , John Martignetti , Karen Heath
发明人： Scott Friedman , Dan Li , Goutham Narla , John Martignetti , Karen Heath
IPC分类号： A61K48/00 , C12Q1/68 , G01N33/53 , G01N33/567 , G01N33/574
CPC分类号： A61K48/005 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/154 , C12Q2600/172 , G01N33/57407 , G01N2333/4703
摘要： The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.
摘要翻译：本发明涉及鉴定蛋白质KLF6（KLF6）的肿瘤抑制活性以及相关的诊断和治疗组合物和方法。这种肿瘤抑制活性的发现也提供筛选目标，特别是筛选克隆基因失活或改变的化合物。

3. 发明申请

US20130035243A1 KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK 审中-公开
标题翻译： KLF6替代性淋巴细胞型和与增加癌症风险相关的GERMLINE KLF6 DNA多态性
公开(公告)号：US20130035243A1
公开(公告)日：2013-02-07
申请号：US13529974
申请日：2012-06-21
申请人： John Martignetti , Goutham Narla , Scott Friedman
发明人： John Martignetti , Goutham Narla , Scott Friedman
IPC分类号： C12Q1/68 , G01N33/574 , C40B30/00
CPC分类号： C12N15/113 , C07K14/4703 , C12N15/111 , C12N2310/14 , C12N2320/33 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLF6wt), in particular any one of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods for diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein.
摘要翻译：公开了通过鉴定野生型KLF6（KLF6wt）的可变剪接的同种型，特别是选自以下的任何一种的方法：鉴定和诊断患者中某些类型的癌症及其前期的方法：KLF6剪接变体 - 1（KLF6SV1），KLF6剪接变体-2（KLF6SV2）和KLF6剪接变体-3（KLF6SV3）。还公开了使用本文鉴定的多肽和多核苷酸诊断癌症的方法，以及通过抑制本文鉴定的多核苷酸和多肽来治疗某些类型的癌症的方法。

4. 发明申请

US20090325150A1 KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK 审中-公开
标题翻译： KLF6替代性淋巴细胞型和与增加癌症风险相关的GERMLINE KLF6 DNA多态性
公开(公告)号：US20090325150A1
公开(公告)日：2009-12-31
申请号：US11572645
申请日：2005-08-01
申请人： John Martignetti , Goutham Narla , Scott Friedman
发明人： John Martignetti , Goutham Narla , Scott Friedman
IPC分类号： C12Q1/68
CPC分类号： C12N15/113 , C07K14/4703 , C12N15/111 , C12N2310/14 , C12N2320/33 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136
摘要： Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLFwt), in particular anyone of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein.
摘要翻译：公开了通过鉴定野生型KLF6（KLFwt）的可变剪接的同种型，特别是选自KLF6剪接变体-1的任何同种型，鉴定和诊断患者中某些类型的癌症及其前期的方法（KLF6SV1），KLF6剪接变体-2（KLF6SV2）和KLF6剪接变体-3（KLF6SV3）。还公开了使用本文鉴定的多肽和多核苷酸诊断癌症的方法，以及通过抑制本文鉴定的多核苷酸和多肽来治疗某些类型的癌症的方法。

5. 发明申请

US20050221336A1 Mutations in capillary morphogenesis gene-2 (CMG-2) and use thereof 审中-公开
标题翻译：毛细血管形态发生基因-2（CMG-2）的突变及其用途
公开(公告)号：US20050221336A1
公开(公告)日：2005-10-06
申请号：US10939321
申请日：2004-09-09
申请人： John Martignetti , Oonagh Dowling
发明人： John Martignetti , Oonagh Dowling
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/6893 , G01N2800/10 , G01N2800/102 , G01N2800/108
摘要： Mutations and polymorphisms in a particular gene, the capillary morphogenesis gene-2 (CMG-2) have been identified. The mutations have been associated with infantile systemic hyalinosis (ISH) and juvenile hyaline fibromatosis (JHF), as well as conditions associated with these disorders. Described herein are variant CMG-2 nucleic acids and variant CMG-2 polypeptides; cells comprising such variant CMG-2 nucleic acids and/or expressing variant CMG-2 polypeptides; and methods of diagnosing and treating such disorders and conditions. Variant CMG-2 proteins include those comprising one or more of E220X, G105D, L329, P257insC, 1189T, A357P, and A322S. Variant CMG-2 nucleic acids include those encoding these mutant CMG-2 proteins, as well as silent mutations or polymorphisms.
摘要翻译：已经鉴定了特定基因的突变和多态性，毛细血管形态发生基因-2（CMG-2）。这些突变已经与婴儿系统性透明细胞病（ISH）和青少年透明纤维瘤病（JHF）以及与这些疾病相关的病症相关。本文描述的是变体CMG-2核酸和变体CMG-2多肽; 包含这种变体CMG-2核酸和/或表达变体CMG-2多肽的细胞; 以及诊断和治疗这些疾病和病症的方法。变体CMG-2蛋白包括包含E220X，G105D，L329，P257insC，1189T，A357P和A322S中的一种或多种的那些。变体CMG-2核酸包括编码这些突变型CMG-2蛋白的那些，以及沉默突变或多态性。

6. 发明申请

US20090317823A1 MUTATIONS IN CAPILLARY MORPHOGENESIS GENE-2 (CMG-2) AND USE THEREOF 审中-公开
标题翻译：毛细血管生成基因-2（CMG-2）中的突变及其用途
公开(公告)号：US20090317823A1
公开(公告)日：2009-12-24
申请号：US12537865
申请日：2009-08-07
申请人： John Martignetti , Oonagh Dowling
发明人： John Martignetti , Oonagh Dowling
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , G01N2800/10 , G01N2800/102 , G01N2800/108
摘要： Mutations and polymorphisms in a particular gene, the capillary morphogenesis gene-2 (CMG-2) have been identified. The mutations have been associated with infantile systemic hyalinosis (ISH) and juvenile hyaline fibromatosis (JHF), as well as conditions associated with these disorders. Described herein are variant CMG-2 nucleic acids and variant CMG-2 polypeptides; cells comprising such variant CMG-2 nucleic acids and/or expressing variant CMG-2 polypeptides; and methods of diagnosing and treating such disorders and conditions. Variant CMG-2 proteins include those comprising one or more of E220X, G105D, L329, P257insC, I189T, A357P, and A322S. Variant CMG-2 nucleic acids include those encoding these mutant CMG-2 proteins, as well as silent mutations or polymorphisms.
摘要翻译：已经鉴定了特定基因的突变和多态性，毛细血管形态发生基因-2（CMG-2）。这些突变已经与婴儿系统性透明细胞病（ISH）和青少年透明纤维瘤病（JHF）以及与这些疾病相关的病症相关。本文描述的是变体CMG-2核酸和变体CMG-2多肽; 包含这种变体CMG-2核酸和/或表达变体CMG-2多肽的细胞; 以及诊断和治疗这些疾病和病症的方法。变体CMG-2蛋白包括包含E220X，G105D，L329，P257insC，I189T，A357P和A322S中的一种或多种的那些。变体CMG-2核酸包括编码这些突变型CMG-2蛋白的那些，以及沉默突变或多态性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式